- Home
- LVTX vs PULM Comparison
LVTX vs PULM Comparison
Compare LVTX & PULM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LVTX
- PULM
- Stock Information
- Founded
- LVTX 2016
- PULM 2003
- Country
- LVTX Netherlands
- PULM United States
- Employees
- LVTX N/A
- PULM N/A
- Industry
- LVTX Biotechnology: Pharmaceutical Preparations
- PULM Biotechnology: Pharmaceutical Preparations
- Sector
- LVTX Health Care
- PULM Health Care
- Exchange
- LVTX Nasdaq
- PULM Nasdaq
- Market Cap
- LVTX 34.2M
- PULM 30.9M
- IPO Year
- LVTX 2021
- PULM N/A
- Fundamental
- Price
- LVTX $1.31
- PULM $6.31
- Analyst Decision
- LVTX Hold
- PULM
- Analyst Count
- LVTX 3
- PULM 0
- Target Price
- LVTX $3.17
- PULM N/A
- AVG Volume (30 Days)
- LVTX 61.1K
- PULM 19.7K
- Earning Date
- LVTX 05-20-2025
- PULM 05-09-2025
- Dividend Yield
- LVTX N/A
- PULM N/A
- EPS Growth
- LVTX N/A
- PULM N/A
- EPS
- LVTX N/A
- PULM N/A
- Revenue
- LVTX $11,982,000.00
- PULM $7,806,000.00
- Revenue This Year
- LVTX N/A
- PULM N/A
- Revenue Next Year
- LVTX N/A
- PULM $134.88
- P/E Ratio
- LVTX N/A
- PULM N/A
- Revenue Growth
- LVTX 77.01
- PULM 6.96
- 52 Week Low
- LVTX $0.85
- PULM $1.72
- 52 Week High
- LVTX $3.20
- PULM $10.40
- Technical
- Relative Strength Index (RSI)
- LVTX 61.39
- PULM 49.72
- Support Level
- LVTX $1.03
- PULM $5.31
- Resistance Level
- LVTX $1.20
- PULM $6.07
- Average True Range (ATR)
- LVTX 0.08
- PULM 0.50
- MACD
- LVTX 0.00
- PULM 0.03
- Stochastic Oscillator
- LVTX 87.50
- PULM 63.59
About LVTX LAVA Therapeutics N.V.
LAVA Therapeutics NV is a biotechnology company. It is focused on transforming cancer treatment by developing a platform to selectively induce bispecific antibody utilizing the Gammabody platform for an undisclosed tumor associated antigen for the treatment of cancer.
About PULM Pulmatrix Inc.
Pulmatrix Inc is a clinical-stage biotechnology company. The company is focused on the discovery and development of novel inhaled therapeutic products intended to prevent and treat respiratory diseases and infections with significant unmet medical needs. Pulmatrix designs and develops inhaled therapeutic products based on its proprietary dry powder delivery technology, iSPERSE (inhaled Small Particles Easily Respirable and Emitted), which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. The iSPERSE powders are engineered to be small, dense particles with dispersibility and delivery to airways.